Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus

Ito, Yuichiro; Schyndle, James Van; Nishimura, Takuya; Sugitani, Toshifumi; Kimura, Tomomi

doi:10.1007/s13300-019-00708-w

Cited by 6 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 While 24% of T2DM patients achieved the target HbA1c (≤7%) in our study, the same was achieved by 19.6-22.6% of Japanese patients with the use of other SGLT2i at 12 months, and by 26.5% of patients in a retrospective, real-world, observational study in T2DM patients in Thailand over 16 months follow-up. 30,31 Likewise HbA1c, statistically significant improvements were observed with FPG (52.3 mg/dl) and PPG (103.6 mg/dl) in our study. These improvements were much higher than that reported by Dharmalingam et al at week 24 with remogliflozin 100 mg (17.86 mg/dl and 39.2 mg/dl).…”

Section: Discussionsupporting

confidence: 63%

A real-world clinical experience on the effectiveness of remogliflozin etabonate in management of Indian patients with type II diabetes mellitus

Sengupta¹,

Sengupta²,

Katare

2021

Int J Res Med Sci

View full text Add to dashboard Cite

Background: The aim of the study was to evaluate effectiveness and safety of remogliflozin etabonate in a real-world outpatient setting in type 2 diabetes mellitus (T2DM) patients in India.Methods: A retrospective, observational, single-center study wherein medical records of adult patients (≥18 years old) with T2DM managed with remogliflozin 100 mg for at least three months at the diabetes care center in Jharkhand were retrieved. The effectiveness was assessed in terms of change from baseline in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), total body weight, blood pressure (BP, systolic and diastolic), kidney function tests, and lipid parameters after three months of treatment. Safety was assessed by adverse events (AEs) and serious AEs.Results: Half of the patients received ≥3 concomitant antidiabetic drugs, common being sulphonylureas (92%), and metformin (91%). Remogliflozin treatment resulted in a significant mean reduction from baseline in HbA1c [-1.99 (0.12%); p<0.001], FPG [-52.3 (4.31) mg/dl; p<0.001] and PPG [-103.6 (7.10) mg/dl; p<0.001). Bodyweight reduction was not statistically significant [-0.1 (10.12) kg]. A significant reduction was observed in the systolic BP [-15.9 (2.21) mmHg; p<0.001] and diastolic BP [-3.3 (0.95) mmHg; p=0.001]. Commonly reported AE was heartburn (51.4%) and urinary tract infections (34.2%). No serious AEs were reported. The mean estimated glomerular filtration rate showed a statistically significant reduction of -1.55 (0.61) ml/min. The lipid parameter findings were non-significant.Conclusions: The real-world experience of remogliflozin administered concomitantly with other antidiabetic drugs was effective and well-tolerated in Indian patients with T2DM.

show abstract

Section: Discussionsupporting

confidence: 63%

A real-world clinical experience on the effectiveness of remogliflozin etabonate in management of Indian patients with type II diabetes mellitus

Sengupta¹,

Sengupta²,

Katare

2021

Int J Res Med Sci

View full text Add to dashboard Cite

show abstract

“…In a large nation‐wide Canadian cohort study by Brown et al, 1520 patients were analysed 3 to 6 months after dapagliflozin initiation and demonstrated a mean HbA1c reduction of 0.9%, mean weight reduction of 2.2 kg and drop in systolic blood pressure by 3.7 mm Hg—effects that are largely aligned with the magnitude of effects reported in clinical trials . Ito et al conducted a larger cohort study involving just over 150 000 T2D patients treated with an oral anti‐hyperglycaemic agent followed for 1 year . SGLT2 inhibitor use was associated with improvements in HbA1c levels from baseline at levels comparable to other agents.…”

Section: Kidney Protection In Cvotsmentioning

confidence: 87%

What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?

Sridhar

Rahman

Cherney

2020

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Over the past 5 years, sodium-glucose cotransport 2 (SGLT2) inhibitors have been increasingly regarded as glycaemic agents with cardiovascular (CV) and renal protective effects. The CV benefits of SGLT2 inhibitors have been well established in patients with type 2 diabetes (T2D) and a range of CV comorbidities at baseline. Subsequently, the renal benefits of SGLT2 inhibitors were established in the CREDENCE trial, a dedicated renal outcome trial where canagliflozin reduced the primary composite renal outcome by 30%. In light of these trials, clinical practice guidelines have rapidly evolved, recommending the use of SGLT2 inhibitors as renal and cardioprotective agents in appropriate patient populations. Accordingly, it is important to have an in-depth understanding of the evidence underlying the use of SGLT2 inhibitors in patients with T2D based on published clinical trials and real-world evidence (RWE) studies, as well as information related to potential safety concerns. To accomplish this, we reviewed the evidence for renal protection and safety with SGLT2 inhibitors in the EMPA-REG OUTCOME, CANVAS Program and DECLARE-TIMI 58 CV safety trials, and in the growing body of evidence emerging from real-world studies. This body of work has shown that SGLT2 inhibitors reduce the risk of surrogate renal endpoints such as albuminuria and mitigate the risk of hard renal endpoints including doubling of serum creatinine and end-stage kidney disease in patients with T2D. K E Y W O R D S diabetic nephropathy, SGLT2 inhibitor 1 | INTRODUCTION Sodium-glucose cotransport-2 (SGLT2) inhibitors have been in clinical use for >5 years and were originally developed and prescribed to achieve additional glucose lowering by inducing glycosuria. As part of Food and Drug Administration (FDA) mandated requirements put in place in 2008, as a novel glucose lowering therapy, SGLT2 inhibitors underwent extensive safety evaluation in cardiovascular outcome trials (CVOTs). Accordingly, over the past 5 years, a large body of evidence has emerged from these CVOTs, and from observational realworld evidence (RWE) studies, as discussed and reviewed elsewhere. 1In stark contrast with other anti-hyperglycaemic agents assessed in CVOTs up to that time, SGLT2 inhibitors were shown to have substantial cardiovascular (CV) and renal protective effects across each medication in the class, and across all subgroups analysed to date.These CVOT results have transformed the way that SGLT2 inhibitors are thought about as therapies for patients with type 2 diabetes (T2D). In perhaps, the same way that ACE inhibitors and ARBs were Vikas S. Sridhar and Habib U. Rahman are the co-first authors.

show abstract

“…The average PDC of SGLT2 inhibitors at one year was between 0.64 and 0.79 [ 41 , 42 ]. Likewise, the proportion of patients who continued to take SGLT2 inhibitors at one year ranged between 44.3 and 72.1% [ 42 , 43 ].…”

Section: Sodium Glucose Co-transporter-2 Inhibitorsmentioning

confidence: 99%

Adherence and persistence rates of major antidiabetic medications: a review

Lee

2022

Diabetol Metab Syndr

View full text Add to dashboard Cite

The objective of this paper was to review the adherence and persistence rates of major antidiabetic medication classes (i.e., metformin, sulfonylureas, sodium glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, insulin, glucagon-like peptide-1 receptor agonists, and thiazolidinediones) by summarizing the major findings of the studies published since 2017. In addition, we reported the potential causes for low adherence and persistence of antidiabetic medications. Based on the literature, the highest rate of adherence and persistence was consistently observed in metformin users. Second to metformin were sodium glucose cotransporter-2 inhibitors. Injectable therapies such as insulin and glucagon-like peptide-1 receptor agonists trailed low on the adherence and persistence rates. To the best of our knowledge, no studies published since the year 2017 analyzed the adherence and persistence of thiazolidinediones independently. The most frequently cited cause for low adherence and persistence was the severity of adverse events. Baseline characteristics (e.g., baseline HbA1c level), demographic information (e.g., age, gender, or ethnicity), and comorbidity profiles also had significant impacts on adherence and persistence in patients with type 2 diabetes mellitus.

show abstract

Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus

Cited by 6 publications

References 27 publications

A real-world clinical experience on the effectiveness of remogliflozin etabonate in management of Indian patients with type II diabetes mellitus

A real-world clinical experience on the effectiveness of remogliflozin etabonate in management of Indian patients with type II diabetes mellitus

What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?

Adherence and persistence rates of major antidiabetic medications: a review

Contact Info

Product

Resources

About